Orthobond Received FDA De Novo Approval for Antibacterial Technology

Orthobond received on April 5th de novo approval for the company’s spinal fusion device with quaternary ammonium compound coating. Orthobond’s antibacterial treatment, Ostaguard™, covalently bonds its antimicrobial, polycationic molecules to the surface of an implant before packaging and sterilization….
By: Knobbe Martens
Previous Story

Payroll Select Services Experienced Data Breach Following Unauthorized Access to Computer Network

Next Story

Trending in Telehealth: April 2 – April 8, 2024